• Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off
Reading...
Front

How to study your flashcards.

Right/Left arrow keys: Navigate between flashcards.right arrow keyleft arrow key

Up/Down arrow keys: Flip the card between the front and back.down keyup key

H key: Show hint (3rd side).h key

A key: Read text to speech.a key

image

Play button

image

Play button

image

Progress

1/22

Click to flip

22 Cards in this Set

  • Front
  • Back
Statin Efffects
Dec LDL
Dec VLDL
Dec Thrombus
Inc Plaque Stability
Inc endothelial function
Dec inflammation
Dec. oxygen stress
Statin MOA
HMG-CoA Reductase Inh
Main drop is from LDL Clearance (now used to make cholesterol)
Transported through OATs
Atorvastatin A/E
Skeletal muscle toxicity
Hepatotoxicity
Increase likelihood of Diabetes
Inc K+
Inc myoglobin (renal damage)
Atorvastatin Metabolism
CYP3A4
Simvastatin Differences
More hydrophobic
More extra-hepatic effects
Simvastatin Metabolism
CYP3A4
Rosuvastatin Differences
More hydrophobic
More Extra-hepatic efffects
More effect on LDLs
Genfibrozil increases blood levels
Rosuvastatin Metabolism
Biliary excretion
Colesevelam Drug Type
Anti-hyperlipidemic
Sequestrin
Colesevelam MOA
Polymer & anion exchange resin
Colesevelam Effects
Dec LDL
Can inc VLDL
Dec glysolyated Hb in T2D
Colesevelam A/E
GI (fewer than most)
Dec fat sol vitamins
Dec neg charged or lipid sol drugs
Ezetimibe Drug Type and MOA
Antihyperlipidemic
Blocks NPC1L1 cholesterol transport
Ezetimibe Effects & combo med
Dec LDL
Dec atherosclerotic thickening
Statin combo
Ezetimibe A/E
Hepatotoxicity
Ezetimibe metabolism
Glucuronidated
Enterohepatic recycling
Nicotinic Acid MOA & Effects
Inc HDL
Dec VLDL
Adipocyte receptor (GPR109A) inhibits HSL activation by beta receptors and protein kinase A
Nicotinic Acid A/E
GI
Flushing
Dec insulin sensitivity
Hyperuricemia
Hepatotoxicity
Fenofibrate Drug Type & MOA
Antihyperlipidemic
PPAR-alpha agonist
Fenofibrate Effects
Inc HDL
Dec VLDL
Inc oxidation of FA in liver
Dec synth of apoCIII in liver
Skeletal muscle inc LPL
Dec neuropathy and retinopathy in T2D
Fenofibrate A/E
Cholelithiasis
Venous thrombosis
Pulmonary embolism
Myopathy
Fenofibrate Metabolism
Hepatic